Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study

详细信息    查看全文

• 作者：Roberto Petrioli ; Edoardo Francini ; Anna Ida Fiaschi ; Letizia Laera…
• 关键词：Bevacizumab ; Cisplatin ; Gemcitabine ; Maintenance ; Lung cancer ; Vinorelbine
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：32
• 期：4
• 全文大小：209 KB
• 参考文献：1. Parkin, DM, Bray, F, Ferlay, J, Pisani, P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: pp. 153-156 CrossRef
  2. Schrump, DS, Nguyen, DM (2005) Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol 32: pp. 488-502 CrossRef
  3. Ferrara, N, Hillan, KJ, Gerber, HP, Novotny, W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: pp. 391-400 CrossRef
  4. Crinò, L, Dansin, E, Garrido, P, Griesinger, F, Laskin, J, Pavlakis, N, Stroiakovski, D, Thatcher, N, Tsai, CM, Wu, YL, Zhou, C (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11: pp. 733-740 CrossRef
  5. Sandler, A, Gray, R, Perry, MC, Brahmer, J, Schiller, JH, Dowlati, A, Lilenbaum, R, Johnson, DH (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: pp. 2542-2550 CrossRef
  6. Reck, M, Pawel, J, Zatloukal, P, Ramlau, R, Gorbounova, V, Hirsh, V, Leighl, N, Mezger, J, Archer, V, Moore, N, Manegold, C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 27: pp. 1227-1234 CrossRef
  7. Reck, M, Pawel, J, Zatloukal, P, Ramlau, R, Gorbounova, V, Hirsh, V, Leighl, N, Mezger, J, Archer, V, Moore, N, Manegold, C (2010) Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: pp. 1804-1809 CrossRef
  8. Ferrara, N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: pp. 581-611 CrossRef
  9. Kerbel, RS (2008) Tumor angiogenesis. N Engl J Med 358: pp. 2039-2049 CrossRef
  10. Zhan, P, Wang, J, Lv, XJ, Ang, Q, Qiu, LX, Lin, XQ, Yu, LK, Song, Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with metaanalysis. J Thorac Oncol. 4: pp. 1094-1103 CrossRef
  11. Winton, T, Livingston, R, Johnson, D, Rigas, J, Johnston, M, Butts, C, Cormier, Y, Goss, G, Inculet, R, Vallieres, E, Fry, W, Bethune, D, Ayoub, J, Ding, K, Seymour, L, Graham, B, Tsao, MS, Gandara, D, Kesler, K, Demmy, T, Shepherd, F (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-lung cancer. N Engl J Med 352: pp. 2589-2597 CrossRef
  12. Fossella, F, Pereira, JR, Pawel, J, Pluzanska, A, Gorbounova, V, Kaukel, E, Mattson, KV, Ramlau, R, Szczesna, A, Fidias, P, Millward, M, Belani, CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: pp. 3016-3034 CrossRef
  13. Smit, EF, Meerbeeck, JP, Lianes, P, Debruyne, C, Legrand, C, Schramel, F, Smit, H, Gaafar, R, Biesma, B, Manegold, C, Neymark, N, Giaccone, G (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol 21: pp. 3909-3917 CrossRef
  14. Gralla, RJ, Gatze
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). The patients were administered six cycles of induction chemotherapy consisting of intravenously (i.v.) Cis 70?mg/m2 on day 1 plus i.v. Gem 1000?mg/m2 on days 1 and 8, plus i.v. Bev 7.5?mg/kg on day 1, every 3?weeks. Patients who did not experience tumor progression remained on maintenance treatment with Bev combined with oral Vnb 60?mg/m2 weekly until occurrence of disease progression or unacceptable toxicity. Thirty-seven patients were enrolled: The median age was 67?years (range 38-1); 22 patients were male, and 30 patients had stage IV tumors. The response rate was 32.4?% (95?% CI 18-9.7). The 9-month disease-control rate was 45.9?%. The median PFS was 8.4?months (95?% CI 4.4-0.7), and the median OS was 18.1?months (95?% CI 15.3-0.8?months). Grade 3- neutropenia occurred in 6 (16.2?%) patients and grade 3- thrombocytopenia in four (10.8?%) patients during induction chemotherapy. Bev- or Vnb-associated toxicities were mild. Switch maintenance treatment with Bev and oral Vnb after first-line Cis, Gem and Bev is feasible in patients with non-squamous NSCLC and may achieve encouraging results in terms of PFS and OS.